Leading-edge Manufacturing Technology, Immune Modulation Technology, Core Treatment Technology
- Intermediate crystallization Technology, Massive production technology with high purity & yield
- Technical barriers equal to those of material patents
Modulation Technology of Cytokine/Chemokine Release
- Modulation of IL-4, IL-6 release
- Modulation of CXCL2/8, CCL26 release
Modulation Technology of Immune Cell Migration and Inflammatory Reaction
- Modulation of neutrophil/ eosinophil migration
- Modulation of Transcription factor STAT3, STAT6
Global Phase 2 Clinical Trials
- Development of First-in-Class RA treatment
- Chemoradiation therapy induced oral mucositis & ARS through Orphan Drug Designation or Fast Track Designation
- Development of oral RA treatment with superior efficacy against Pfizer’s Xeljanz
- Development of first-in-class sepsis treatment in the market without competing drug
- Development of treatment for psoriasis, asthma and atopic dermatitis
Mechanism of Action
Mechanism of action of EC-18: EC-18 promotes the removal of DAMP and PAMP in a short period of time, thus inhibiting the continuous release of neutrophils from blood vessel, excessive infiltration of immune cells and excessive release of cytokines in inflammatory tissues and infection site.
Research Papers and Articles
PLAG alleviates chemotherapy-induced thrombocytopenia via promotion of megakaryocyte/erythrocyte progenitor differentiation in mice. Thrombosis Research 161:84-90, 2018.
PLAG (1-palmitoyl-2-linoleoyl-3-acetyl-rac-glycerol) reduces hepatic injury in concanavalin A-treated mice. Journal of Cellular Biochemistry 119(2):1392-1405, 2018.
PLAG (1-palmitoyl-2-linoleoyl-3-acetyl-rac-glycerol) ameliorates arthritic joints through reducing neutrophil infiltration mediated by IL-6/STAT3 and MIP-2 activation. Oncotarget 8(57):96636-96648, 2017.
The ameliorating effect of 1-palmitoyl-2-linoleoyl-3-acetyl-rac-glycerol on scopolamine-induced memory impairment via acetylcholinesterase inhibition and LTP activation. Behavioural Brain Research 324:58-65.
The Therapeutic Effect of PLAG against Oral Mucositis in Hamster and Mouse Model. Frontiers in Oncology 6:206, 2016
PLAG (1-palmitoyl-2-linoleoyl-3-acetyl-rac-glycerol) augments the therapeutic effect of pegfilgrastim on gemcitabine-induced neutropenia. Cancer Letters 377: 25-31, 2016
PLAG (1-Palmitoyl-2-Linoleoyl-3-Acetyl-rac-Glycerol) Modulates Eosinophil Chemotaxis by Regulating CCL26 Expression from Epithelial Cells. PLoS One, 11(3):e0151758, 2016
Protective effect of EC-18, a synthetic monoacetyldiglyceride on lung inflammation in a murine model induced by cigarette smoke and lipopolysaccharide. International Immunopharmacology: 30: 62-68, 2016
1-Pamitoyl-2-Linoleoyl-3-Acetyl-rac-Glycerol May Reduce Incidence of Gemcitabine-Induced Neutropenia: A Pilot Case-Controlled Study. World Journal of oncology 6(4):410-415, 2015
Effect of 1-palmitoyl-2-linoleoyl-3-acetyl-rac-glycerol on immune functions in healthy adults in a randomized controlled trial. Immune Network, 15(3):150-60, 2015
1-palmitoyl-2-linoleoyl-3-acetyl-rac-glycerol (EC-18) Modulates Th2 Immunity through Attenuation of IL-4. Immune Network, 15(2): 100-109, 2015
EC-18, a synthetic monoacetyldiglyceride (1-palmitoyl-2-linoleoyl-3-acetylglycerol), attenuates the asthmatic response in an aluminum hydroxide/ovalbumin-induced model of asthma. International immunopharmacology 21;18(1):116-23, 2014.
Enteral Administration of a Synthetic Monoacetyldiglyceride Improves Survival in a Murine Model of Abdominal Sepsis. Journal of Trauma. 68(1):62-8, 2010
EC-18, a Synthetic Monoacetyldiacylglyceride, Inhibits Hematogenous Metastasis of KIGB-5 Biliary Cancer Cell in Hamster Model. Journal of Korean medical science 24(3):474-80, 2009
Stimulatory effects of monoacetyldiglycerides on hematopoiesis. Biological & Pharmaceutical Bulletin. 27(7):1121-1125, 2004
Purification and structural determination of hematopoietic stem cell-stimulating monoacetyldiglycerides from Cervus nippon (deer antler). 52(7):874-8, 2004